ImmuPharma PLC
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company's lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lup… Read more
ImmuPharma PLC (IMM) - Net Assets
Latest net assets as of June 2025: GBX336.70K GBX
Based on the latest financial reports, ImmuPharma PLC (IMM) has net assets worth GBX336.70K GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX1.58 Million) and total liabilities (GBX1.24 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX336.70K |
| % of Total Assets | 21.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | -105.62% |
| 10-Year Change | -132.11% |
| Growth Volatility | 102.98 |
ImmuPharma PLC - Net Assets Trend (2004–2024)
This chart illustrates how ImmuPharma PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ImmuPharma PLC (2004–2024)
The table below shows the annual net assets of ImmuPharma PLC from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | GBX-542.86K | -151.39% |
| 2023-12-31 | GBX1.06 Million | -58.14% |
| 2022-12-31 | GBX2.52 Million | -42.83% |
| 2021-12-31 | GBX4.41 Million | -54.29% |
| 2020-12-31 | GBX9.65 Million | +83.23% |
| 2019-12-31 | GBX5.27 Million | -30.88% |
| 2018-12-31 | GBX7.62 Million | +113.26% |
| 2017-12-31 | GBX3.57 Million | -35.55% |
| 2016-12-31 | GBX5.55 Million | +228.09% |
| 2015-12-31 | GBX1.69 Million | -70.37% |
| 2014-12-31 | GBX5.71 Million | +5.58% |
| 2013-12-31 | GBX5.40 Million | -35.81% |
| 2012-12-31 | GBX8.42 Million | -32.69% |
| 2011-12-31 | GBX12.51 Million | -21.69% |
| 2010-12-31 | GBX15.97 Million | -11.69% |
| 2009-12-31 | GBX18.08 Million | +60.88% |
| 2008-12-31 | GBX11.24 Million | +268.52% |
| 2007-12-31 | GBX3.05 Million | -48.18% |
| 2006-12-31 | GBX5.89 Million | +135.06% |
| 2006-03-31 | GBX2.50 Million | +152.17% |
| 2005-03-31 | GBX993.00K | +1.53% |
| 2004-03-31 | GBX978.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to ImmuPharma PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6591214.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX29.81 Million | % |
| Other Components | GBX35.56 Million | % |
| Total Equity | GBX-542.86K | 100.00% |
ImmuPharma PLC Competitors by Market Cap
The table below lists competitors of ImmuPharma PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
QUANTUM RESOURCES
BE:QM3
|
$4.47K |
|
Tariq Glass Industries Ltd
KAR:TGL
|
$4.47K |
|
INTERTAINMENT
MU:ITN
|
$4.47K |
|
PT Merdeka Gold Resources Tbk
JK:EMAS
|
$4.48K |
|
Mitchell Resources Ltd
STU:C8MQ
|
$4.46K |
|
HAPV3Q
SA:HAPV3Q
|
$4.46K |
|
MELCO INTL DEVT
BE:MX7A
|
$4.45K |
|
BIALETTI INDUSTRIE
BE:32B
|
$4.45K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ImmuPharma PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,056,289 to -542,859, a change of -1,599,148 (-151.4%).
- Net loss of 2,483,000 reduced equity.
- Other comprehensive income decreased equity by 6,008,738.
- Other factors increased equity by 6,892,590.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-2.48 Million | -457.39% |
| Other Comprehensive Income | GBX-6.01 Million | -1106.87% |
| Other Changes | GBX6.89 Million | +1269.68% |
| Total Change | GBX- | -151.39% |
Book Value vs Market Value Analysis
This analysis compares ImmuPharma PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-03-31 | GBX0.23 | GBX5.41 | x |
| 2005-03-31 | GBX0.24 | GBX5.41 | x |
| 2006-03-31 | GBX0.04 | GBX5.41 | x |
| 2006-12-31 | GBX0.08 | GBX5.41 | x |
| 2007-12-31 | GBX0.04 | GBX5.41 | x |
| 2008-12-31 | GBX0.14 | GBX5.41 | x |
| 2009-12-31 | GBX0.22 | GBX5.41 | x |
| 2010-12-31 | GBX0.20 | GBX5.41 | x |
| 2011-12-31 | GBX0.15 | GBX5.41 | x |
| 2012-12-31 | GBX0.10 | GBX5.41 | x |
| 2013-12-31 | GBX0.07 | GBX5.41 | x |
| 2014-12-31 | GBX0.07 | GBX5.41 | x |
| 2015-12-31 | GBX0.02 | GBX5.41 | x |
| 2016-12-31 | GBX0.05 | GBX5.41 | x |
| 2017-12-31 | GBX0.03 | GBX5.41 | x |
| 2018-12-31 | GBX0.05 | GBX5.41 | x |
| 2019-12-31 | GBX0.03 | GBX5.41 | x |
| 2020-12-31 | GBX0.05 | GBX5.41 | x |
| 2021-12-31 | GBX0.02 | GBX5.41 | x |
| 2022-12-31 | GBX0.01 | GBX5.41 | x |
| 2023-12-31 | GBX0.00 | GBX5.41 | x |
| 2024-12-31 | GBX0.00 | GBX5.41 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ImmuPharma PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-79.68%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.10% | 0.00% | 0.00x | 1.00x | GBX-96.80K |
| 2005 | 1.51% | 0.00% | 0.00x | 1.01x | GBX-84.30K |
| 2006 | -99.16% | -9932.00% | 0.01x | 1.45x | GBX-2.73 Million |
| 2006 | -42.13% | -4150.22% | 0.01x | 1.24x | GBX-3.07 Million |
| 2007 | -101.08% | -4893.65% | 0.02x | 1.34x | GBX-3.39 Million |
| 2008 | 41.61% | 8205.26% | 0.00x | 1.19x | GBX3.55 Million |
| 2009 | 44.81% | 36.74% | 0.89x | 1.36x | GBX6.29 Million |
| 2010 | -12.39% | -6181.25% | 0.00x | 1.10x | GBX-3.58 Million |
| 2011 | -26.83% | -19735.29% | 0.00x | 1.14x | GBX-4.61 Million |
| 2012 | -45.66% | 0.00% | 0.00x | 1.25x | GBX-4.69 Million |
| 2013 | -68.27% | 0.00% | 0.00x | 1.33x | GBX-4.23 Million |
| 2014 | -50.32% | -1553.45% | 0.03x | 1.24x | GBX-3.44 Million |
| 2015 | -230.54% | -5100.32% | 0.02x | 1.90x | GBX-4.07 Million |
| 2016 | -96.00% | -3230.90% | 0.02x | 1.21x | GBX-5.88 Million |
| 2017 | -174.09% | -4135.93% | 0.03x | 1.40x | GBX-6.58 Million |
| 2018 | -94.54% | -8866.77% | 0.01x | 1.14x | GBX-7.97 Million |
| 2019 | -116.22% | -7858.84% | 0.01x | 1.10x | GBX-6.65 Million |
| 2020 | -71.05% | -5415.78% | 0.01x | 1.13x | GBX-7.83 Million |
| 2021 | -185.20% | -6906.63% | 0.02x | 1.36x | GBX-8.62 Million |
| 2022 | -150.87% | 0.00% | 0.00x | 1.58x | GBX-4.06 Million |
| 2023 | -276.63% | 0.00% | 0.00x | 2.58x | GBX-3.03 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | GBX-2.43 Million |
Industry Comparison
This section compares ImmuPharma PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ImmuPharma PLC (IMM) | GBX336.70K | 0.10% | 3.69x | $4.47K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |